Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.

Francois MercierNassim DjebliMario González-SalesFelix JaminionGeorgina Meneses-Lorente

Published in: Cancer chemotherapy and pharmacology (2022)

These analyses supported that entrectinib at 600 mg/day provides an acceptable benefit-risk ratio in adults with NTRK-, ROS1-, or ALK-positive tumors, considered as rare disease.

Keyphrases

squamous cell carcinoma
small cell lung cancer
cell death
dna damage
reactive oxygen species
advanced non small cell lung cancer